Highlights Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 10:05:25 06/03/2026 pm IST			5-day change	1st Jan Change
5.402 ^EUR	-1.13%		-8.13%	-0.88%

24/02	Centauri Therapeutics Limited announced that it has received £30 million in funding from a group of investors	CI
03/02	Evotec Shares Surge Following Berenberg Buy Recommendation	DP

Highlights

08/01	Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies	MT
08/01	Evotec Remains in Demand on Tradegate – Funding Secured for Subsidiary	DP
07/01	Evotec Continues Upward Trend Following Amgen's Acquisition of Dark Blue	DP
06/01	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million	DJ
05/01	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.	CI
17/12	Evotec SE Equity Buyback announced on August 6, 2024, has expired.	CI
08/12	Sandoz Concludes Purchase of Evotec's Biologics Platform	MT
08/12	Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership	RE
08/12	Novo Holdings Reportedly Plans to Sell 9.4 Million Shares in Evotec	CI
05/12	Sandoz Group AG completed the acquisition of Just-Evotec Biologics EU SAS from Evotec SE.	CI
04/12	Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome	CI
04/12	Evotec SE Starts Phase 2 Study for Treatment of Patients with Alport Syndrome	CI
12/11	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Hopes of Federal Government Reopening	MT
06/11	Evotec SE - to implement share repurchase program	RE
06/11	Evotec SE announces an Equity Buyback for 290,000 shares, for ?3 million.	CI
06/11	Evotec SE authorizes a Buyback Plan.	CI
05/11	Analyst recommendations: Nvidia, Tesla, IBM, AMD, Amgen…
05/11	Evotec SE Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
05/11	Evotec SE Confirms Earnings Guidance for the Full Year 2025	CI
05/11	Evotec Q3 Loss Widens, Revenue Falls; Shares Down Pre-Bell	MT
05/11	Evotec Disappoints in Third Quarter - Sells JEB to Sandoz	DP
05/11	Evotec Set for Windfall from Sale of Toulouse Plant to Sandoz	RE
05/11	Evotec Widens Operating Loss, Division Sale Boosts Share Price	DP
05/11	Evotec to Sell Just - Evotec Biologics EU, Site in France to Sandoz	MT
27/25/27	Evotec Secures $25 Million Funding Under Bristol Myers Squibb Neuroscience Partnership	MT